KRAS (Kirsten rat sarcoma), is an important oncogene and its mutation is known to drive abnormal cell cycle progression and tumorigenesis in NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer (CRC). This evidence concerns the gene KRAS and non-small cell lung carcinoma.